OnKure Therapeutics, Inc. (OKUR) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

0.5x

Market Cap

$144.77M

MomentumView details →

1D Return

+0.42%

YTD Return

+23.80%

RSI (14)

34.3

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

0.5x

Market Cap

$144.77M

RSI (14)

34.3

MomentumView details →

1D Return

+0.42%

YTD Return

+23.80%

SummaryUpdated Jun 1, 2026

OnKure Therapeutics, Inc. (NASDAQ:OKUR) is a clinical-stage biotechnology company founded in 2011 and headquartered in Boulder, Colorado. The company specializes in discovering and developing precision oncology medicines, with a particular focus on creating selective inhibitors of histone deacetylases (HDACs) for treating various forms of cancer. OnKure went public through a merger transaction and currently trades on NASDAQ, representing one of the smaller players in the competitive oncology drug development space.

Ask drillr about OnKure Therapeutics, Inc. →

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−34.11%

ROA (TTM)

−32.73%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+33.33%

FCF YoY

+18.95%

Revenue CAGR 3Y

—

EPS CAGR 3Y

−11.39%

EBITDA YoY

+11.63%

EarningsView details →

EPS (Actual)

−$0.31

EPS Surprise

42.06%

Beats (12Q)

6/12

Next Q EPS Est

−$0.41

Avg Surprise (4Q)

102.33%

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

26.75x

Quick Ratio

26.75x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−58.70M

Op. CF (TTM)

−47.84M

Next earningsNov 5, 2026 →

Latest newsMore news →

OnKure Therapeutics repriced outstanding stock options for its CEO, CMO, and CFO to $4.14 per share, effective August 7, 2026, subject to an 18-month retention requirement.23d ago

OnKure Therapeutics, Inc. elected R. Michael Carruthers, Valerie M. Jansen, M.D., Ph.D., and Edward T. Mathers as Class II directors, effective June 3, 2026.93d ago

Similar companies

Inovio Pharmaceuticals, Inc.INO Biomea Fusion, Inc.BMEA Unicycive Therapeutics, Inc.UNCY Equillium, Inc.EQ Milestone Pharmaceuticals Inc.MIST NRx Pharmaceuticals, Inc.NRXP Find similar companies →

Latest newsMore news →

OnKure Therapeutics repriced outstanding stock options for its CEO, CMO, and CFO to $4.14 per share, effective August 7, 2026, subject to an 18-month retention requirement.23d ago OnKure Therapeutics, Inc. elected R. Michael Carruthers, Valerie M. Jansen, M.D., Ph.D., and Edward T. Mathers as Class II directors, effective June 3, 2026.93d ago